We are advancing a set of full- and partial agonistic HGF-mimetic antibodies that bind to MET with high affinity. By promoting receptor dimerization and activation, the full agonistic antibodies resemble the molecular action of HGF and evoke the same biological activities elicited by the natural ligand. Meanwhile, the partial agonistic antibodies have the capability to selectively activate intracellular signaling pathways that are relevant to specific pathologies. These MET-targeted agonistic antibodies overcome all the intrinsic limitations of HGF and allow us to fully exploit the promising therapeutic potential of the HGF/MET pathway in the clinic.
“Our lead candidate, AGMB-101, a full MET agonist, enables us to demonstrate the superiority of our approach which substitutes the potent but short-lived action of HGF with the specific and long-lasting activity inherent to monoclonal antibodies in order to achieve effective and persistent disease modification in a number of indications with high unmet medical need.”
Torsten Dreier, Chief Development Officer